RAM
VKTX icon

Riggs Asset Management’s Viking Therapeutics VKTX Stock Holding History

Riggs Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$398 – 714
2024
Q4 		$398 Hold
10
– – ﹤0.01% 585
2024
Q3 		$634 Hold
10
– – ﹤0.01% 509
2024
Q2 		$531 Hold
10
– – ﹤0.01% 527
2024
Q1 		$820 Buy
+10
New +$445 ﹤0.01% 453

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Riggs Asset Management's VKTX Position: Q1 2025 in Review

Riggs Asset Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 10 shares — an estimated $398 sold.

Riggs Asset Management first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $820 in Q1 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Riggs Asset Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Riggs Asset Management sold 10 Viking Therapeutics shares in Q1 2025, an estimated $398.
  • Riggs Asset Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • Riggs Asset Management's Viking Therapeutics position peaked at $820 in Q1 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Riggs Asset Management's 13F filing for Q1 2025, filed 29 Apr 2025.